37% Growth, Consolidated Loss

Religare's insurance fortress is working. Care delivered 37% GWP growth—far ahead of its prior 18–24% guidance and outpacing the industry's 32% retail tailwind. The company posted ₹163 crore profit from Care alone and is commanding 6.7% of the overall health insurance market, 24% within the retail-only segment. On that scorecard alone, it is a hold. But scroll down one line on the consolidated P&L and the franchise strength evaporates: the group posted a ₹47 crore loss, a swing of ₹76.73 crore from a ₹5.73 crore profit a year ago. The insurance business is being strangled by three rebuilding financial services arms—housing finance still unprofitable 12+ months past its profitability target, an NBFC sitting on ₹600 crore idle cash for six months, and a broking unit with flat sequential revenue despite profitability gains. That gap—star performer at the operating unit, loss at the group level—is the story of this quarter.

The market took the result with a shrug and then a sell. The stock dropped 2.21% on day 1, extended the loss to −3.73% by day 3. The move is modest and fading—suggesting the market had priced in some of the FS drag, or that Care's 37% growth is keeping institutional buyers engaged despite the consolidated loss. FII ownership climbed to 9.64% (+1.79pp QoQ), DII to 9.33% (+0.81pp), with promoters steady at 30.56%. The stock is trading ₹231.9, below its 20-, 50-, and 200-day moving averages (₹244.72, ₹253.7, ₹238.95 respectively), off its all-time high of ₹280 by 17.18%. RSI at 33.5 suggests neutral territory, not capitulation. The 52-week range of ₹196–₹280 places the current price in the lower-middle band—neither a deep drawdown nor a reversal signal. The incoming FII/DII are not panic-selling, but they are also not aggressively buying the dip.

Hold. Religare Enterprises in Q1 FY27 is a study in conglomerate leverage—not financial leverage (though 4.3x is elevated), but *strategic* leverage. The insurance franchise is best-in-class; Care's 37% GWP growth, ₹163 Cr profit, and commanding market position validate the core business. But that strength is being weaponized to fund three unproven, loss-making financial services arms. The consolidated group loss of ₹47 Cr is not a one-off—it's structural until housing finance and NBFC prove profitability. Worse, the demerger—the mechanism that was supposed to unlock value by separating the group into two focused entities—is blocked by RBI with no path forward disclosed. Management's track record on timing has been mixed: housing profitability target missed, NBFC launch pushed, demerger target abandoned. This quarter is *steady execution* on Care, not a step-change. The number to track from here is **consolidated net profit trajectory**. If Q2 sees housing losses narrow and NBFC deployment commence, the bear case weakens. If both remain stalled, the case for holding a conglomerate discount turns from 'unfair to ignore' to 'an albatross.' The demerger re-engagement timeline is a make-or-break catalyst.